MGH Neurology
Share
The Massachusetts General Hospital Department of Neurology integrates compassionate care with state-of-the-art research and rigorous medical training. Our expert subspecialty care is aided by the latest medical technology, from life-saving intervention for acute brain trauma to skillful management of chronic illnesses.
In Healey ALS MyMatch, participants and biomarker driven trial design are at the center of the therapeutic development process.
Watch this video on our website: https://www.massgeneral.org/neurology/als/research/healey-mymatch
06/17/2026
Dr. Suma Babu recently joined Dr. Ryan Jacobson of Rush University on an ANA Investigates podcast.
They discussed Healey ALS MyMatch, the hope it brings to ALS drug development, and latest updates.
Listen to the podcast here: https://sites.libsyn.com/203825/site/ana-investigates-als-research-and-the-healey-alsmymatch
American Neurological Association
ANA Investigates: ANA investigates ALS Research and Healey ALS MyMatch In this episode, we will focus on the latest in the research on ALS. ALS remains a devastating disease, but the field is now at an inflection point with a growing pipeline of precision therapies, trial-ready sites, and a new generation of clinician scientists - yet barriers persist. There is dise...
06/15/2026
Tofersen is a therapy used for treating people living with SOD1 ALS. Before tofersen was an FDA approved drug, it was available through an expanded access protocol (EAP) at Mass General Brigham.
This EAP shows that early access to complex gene-directed therapies can be delivered safely and efficiently in ALS care. The study also provides guidance to clinicians on safety monitoring and operationalizing such research protocols while integrating into ALS clinical care.
Learn more about the clinical and operational experience of this EAP: https://onlinelibrary.wiley.com/doi/10.1002/mus.70310
Optimizing Research Operations and Resource Utilization in ALS Care: Insights From the Tofersen Antisense Oligonucleotide Expanded Access Protocol Introduction/Aims Tofersen is a gene-targeted therapy for individuals with superoxide dismutase 1 (SOD1) (+) amyotrophic lateral sclerosis (ALS). Prior to U.S. Food and Drug Administration (FDA) app...
06/01/2026
New ALS therapy shows researchers "this illness can be stopped" A new drug, called tofersen, can radically slow and even reverse the course of ALS.
05/29/2026
Read the latest Healey & AMG Center newsletter on clinical trials and observational research: https://conta.cc/4wSdJMP
Learn more about research programs, clinical trial updates, publications, and awards.
Updates from the Sean M. Healey & AMG Center for ALS Email from Massachusetts General Hospital Spring 2026 Newsletter: Clinical Trials & Observational Research Sean M. Healey & AMG Center for ALS Spring 2026 newsletter: Clinical trials & observational
Click here to claim your Sponsored Listing.
Category
Address
15 Parkman Street
Boston, MA
02114
